SCHEMBL1496893

SCHEMBL1496893

Cc1cccc(CCNC(=O)N(CCN(C)C)Cc2ccc(C(=O)Nc3cscc3NC(=O)OC(C)(C)C)nc2)c1

nearest known ligand 0.37

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.37
PDCD1 Q15116 4/20 0.36
CD274 Q9NZQ7 4/20 0.36
RAF1 P04049 2/20 0.36
CNR1 P21554 1/20 0.35
ROCK1 Q13464 3/20 0.34
HDAC1 Q13547 1/20 0.34
HTR5A P47898 2/20 0.34
PTGER4 P35408 1/20 0.34
LMNA P02545 1/20 0.34
MAPT P10636 1/20 0.34
ATM Q13315 1/20 0.34
ROCK2 O75116 2/20 0.34
SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1496945 0.93 HIF1A (0.41) PDCD1CD274RAF1CNR1ROCK1
SCHEMBL1496862 0.92 HTR5A (0.40) PDCD1CD274RAF1ROCK1HDAC1
SCHEMBL12831883 0.91 RAF1 (0.37) PDCD1CD274RAF1CNR1ROCK1
SCHEMBL1497043 0.89 HIF1A (0.42) HDAC1HTR5AROCK2
SCHEMBL1496875 0.89 HTR5A (0.39) POLBPDCD1CD274ROCK1HDAC1
SCHEMBL1496860 0.89 ROCK2 (0.38) PDCD1CD274RAF1ROCK1HDAC1
SCHEMBL1496892 0.88 CTSK (0.38) PDCD1CD274ROCK1HDAC1HTR5A
SCHEMBL1496843 0.88 KMT2A (0.40) RAF1CNR1ROCK1HDAC1MAPT
SCHEMBL1497072 0.88 PDCD1 (0.38) PDCD1CD274RAF1CNR1ROCK1
SCHEMBL1496858 0.88 MEN1 (0.41) POLBPDCD1CD274ROCK1HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8288380-B2 Thiophenediamine derivative having urea structure SANTEN PHARMACEUTICAL CO., LTD. (JP) 2012-10-16 US disclosed
US-20120202808-A1 NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE SANTEN PHARMACEUTICAL CO., LTD. (JP) 2012-08-09 US disclosed
US-20120202808-A1 NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE SANTEN PHARMACEUTICAL CO., LTD. (JP) 2012-08-09 US disclosed
EP-2292611-B1 NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE SANTEN PHARMACEUTICAL CO LTD (JP) 2012-07-25 EP disclosed
EP-2292611-B1 NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE SANTEN PHARMACEUTICAL CO LTD (JP) 2012-07-25 EP disclosed
US-8198271-B2 Thiophenediamine derivative having urea structure SANTEN PHARMACEUTICAL CO., LTD. (JP) 2012-06-12 US disclosed
US-20110077244-A1 NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-03-31 US disclosed
EP-2292611-A1 NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE Santen Pharmaceutical Co., Ltd (JP) 2011-03-09 EP disclosed
EP-2292611-A1 NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE Santen Pharmaceutical Co., Ltd (JP) 2011-03-09 EP disclosed
WO-2009142321-A1 NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE 参天製薬株式会社 (JP) 2009-11-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120202808-A1 NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE CBR1, NAT1, PRMT1 POLB 2414/4885PDCD1 4160/4885CD274 4096/4885
US-20110077244-A1 NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE HNMT, HRH4, CHRM1 POLB 3976/4885PDCD1 4547/4885CD274 4718/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.